These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 17425412)

  • 21. Hemolysis from ABO Incompatibility.
    Simmons DP; Savage WJ
    Hematol Oncol Clin North Am; 2015 Jun; 29(3):429-43. PubMed ID: 26043383
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Refractory response to platelet transfusion therapy.
    Eisenberg S
    J Infus Nurs; 2010; 33(2):89-97. PubMed ID: 20228646
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ensuring quality in platelet immunology.
    Metcalfe P
    Vox Sang; 2007 Nov; 93(4):287-8. PubMed ID: 18070270
    [No Abstract]   [Full Text] [Related]  

  • 24. Nonfatal intravascular hemolysis in a pediatric patient after transfusion of a platelet unit with high-titer anti-A.
    Harris SB; Josephson CD; Kost CB; Hillyer CD
    Transfusion; 2007 Aug; 47(8):1412-7. PubMed ID: 17655585
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transfusion of apheresis platelets and ABO groups.
    Vox Sang; 2005 Apr; 88(3):207-21. PubMed ID: 15787735
    [No Abstract]   [Full Text] [Related]  

  • 26. The clinical implications of platelet transfusions associated with ABO or Rh(D) incompatibility.
    Lozano M; Cid J
    Transfus Med Rev; 2003 Jan; 17(1):57-68. PubMed ID: 12522772
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ABO-incompatible platelets are associated with increased transfusion reaction rates.
    Malvik N; Leon J; Schlueter AJ; Wu C; Knudson CM
    Transfusion; 2020 Feb; 60(2):285-293. PubMed ID: 31912889
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acute haemolytic reaction secondary to an ABO minor mismatched platelet transfusion from a group A blood donor.
    Swain F; Daly J; Baidya S; Wilson B; Morrison J; Liew YW; Powley T; Jivan Y; Bryant S; Allen A; Crampton N
    Transfus Med; 2019 Apr; 29(2):133-135. PubMed ID: 30900358
    [No Abstract]   [Full Text] [Related]  

  • 29. Risk of Rh(D) alloimmunization after transfusion of platelets from D+ donors to D- recipients.
    Cid J; Lozano M
    Transfusion; 2005 Mar; 45(3):453; author reply 453-4. PubMed ID: 15752167
    [No Abstract]   [Full Text] [Related]  

  • 30. Apheresis platelet transfusions: does ABO matter?
    Herman JH; King KE
    Transfusion; 2004 Jun; 44(6):802-4. PubMed ID: 15157242
    [No Abstract]   [Full Text] [Related]  

  • 31. Acute Intravascular Hemolysis Following an ABO Non-Identical Platelet Transfusion: A Case Report and Literature Review.
    Moinuddin IA; Millward P; Fletcher CH
    Am J Case Rep; 2019 Jul; 20():1075-1079. PubMed ID: 31332158
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Donor selection in platelet transfusion therapy of alloimmunized thrombocytopenic patients.
    Duqesnoy RJ
    Prog Clin Biol Res; 1978; 28():229-43. PubMed ID: 88057
    [No Abstract]   [Full Text] [Related]  

  • 33. Hemolysis following platelet transfusions from ABO-incompatible donors.
    Pierce RN; Reich LM; Mayer K
    Transfusion; 1985; 25(1):60-2. PubMed ID: 2578692
    [TBL] [Abstract][Full Text] [Related]  

  • 34. How we treat: risk mitigation for ABO-incompatible plasma in plateletpheresis products.
    Fontaine MJ; Mills AM; Weiss S; Hong WJ; Viele M; Goodnough LT
    Transfusion; 2012 Oct; 52(10):2081-5. PubMed ID: 22414003
    [No Abstract]   [Full Text] [Related]  

  • 35. [Platelet antigens and antibodies against them].
    Zotikov EA
    Biull Eksp Biol Med; 2000 Mar; 129(3):244-7. PubMed ID: 10776555
    [No Abstract]   [Full Text] [Related]  

  • 36. Evaluating safety and cost-effectiveness of platelets stored in additive solution (PAS-F) as a hemolysis risk mitigation strategy.
    Pagano MB; Katchatag BL; Khoobyari S; Van Gerwen M; Sen N; Rebecca Haley N; Gernsheimer TB; Hess JR; Metcalf RA
    Transfusion; 2019 Apr; 59(4):1246-1251. PubMed ID: 30592057
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Platelet transfusions, refractory states, contribution of laboratories].
    Kaplan C
    Ann Med Interne (Paris); 1994; 145(5):350-1. PubMed ID: 7985947
    [No Abstract]   [Full Text] [Related]  

  • 38. [Refractoriness to platelet transfusion].
    Tsurumi H; Hara T; Moriwaki H
    Ryoikibetsu Shokogun Shirizu; 1998; (21 Pt 2):332-4. PubMed ID: 9833505
    [No Abstract]   [Full Text] [Related]  

  • 39. Transfusion of platelets and plasma products.
    Menitove JE; Aster RH
    Clin Haematol; 1983 Feb; 12(1):239-66. PubMed ID: 6340882
    [No Abstract]   [Full Text] [Related]  

  • 40. Transfusion of ABO-nonidentical platelets is not associated with adverse clinical outcomes in cardiovascular surgery patients.
    Lin Y; Callum JL; Coovadia AS; Murphy PM
    Transfusion; 2002 Feb; 42(2):166-72. PubMed ID: 11896330
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.